Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of sacituzumab tirumotecan in previously treated neuroendocrine carcinoma
ChiCTR2600133243Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan in neuroendocrine carcinoma (NEC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective response rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on ChiCTR2600133243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133243.